Faricimab (Vabysmo ®) for visual impairment due to diabetic macular oedema. HTA ID: 22061

Assessment Status Awaiting full HTA submission from Applicant
HTA ID 22061
Drug Faricimab
Brand Vabysmo ®
Indication For the treatment of adult patients with visual impairment due to diabetic macular oedema (DMO).
Assessment Process
Rapid review commissioned 29/08/2022
Rapid review completed 04/10/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of faricimab (Vabysmo®) for the treatment of DMO compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 25/10/2022
Pre-submission consultation with Applicant 03/10/2023